The role of NMDA receptor in neurobiology and treatment of major depressive disorder

Evidence from translational research

Meysam Amidfar, Marie Woelfer, Gislaine Z. Réus, João Quevedo, Martin Walter, Yong Ku Kim

Research output: Contribution to journalReview article

Abstract

There is accumulating evidence demonstrating that dysfunction of glutamatergic neurotransmission, particularly via N-methyl-d-aspartate (NMDA) receptors, is involved in the pathophysiology of major depressive disorder (MDD). Several studies have revealed an altered expression of NMDA receptor subtypes and impaired NMDA receptor-mediated intracellular signaling pathways in brain circuits of patients with MDD. Clinical studies have demonstrated that NMDA receptor antagonists, particularly ketamine, have rapid antidepressant effects in treatment-resistant depression, however, neurobiological mechanisms are not completely understood. Growing body of evidence suggest that signal transduction pathways involved in synaptic plasticity play critical role in molecular mechanisms underlying rapidly acting antidepressant properties of ketamine and other NMDAR antagonists in MDD. Discovering the molecular mechanisms underlying the unique antidepressant actions of ketamine will facilitate the development of novel fast acting antidepressants which lack undesirable effects of ketamine. This review provides a critical examination of the NMDA receptor involvement in the neurobiology of MDD including analyses of alterations in NMDA receptor subtypes and their interactive signaling cascades revealed by postmortem studies. Furthermore, to elucidate mechanisms underlying rapid-acting antidepressant properties of NMDA receptor antagonists we discussed their effects on the neuroplasticity, mostly based on signaling systems involved in synaptic plasticity of mood-related neurocircuitries.

Original languageEnglish
Article number109668
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume94
DOIs
Publication statusPublished - 2019 Aug 30

Fingerprint

Translational Medical Research
Neurobiology
Major Depressive Disorder
Antidepressive Agents
Ketamine
Neuronal Plasticity
Therapeutics
Treatment-Resistant Depressive Disorder
aspartic acid receptor
Synaptic Transmission
Signal Transduction
Brain

Keywords

  • Ketamine
  • Major depressive disorder
  • Memantine
  • NMDA receptor
  • Synaptic plasticity

ASJC Scopus subject areas

  • Pharmacology
  • Biological Psychiatry

Cite this

The role of NMDA receptor in neurobiology and treatment of major depressive disorder : Evidence from translational research. / Amidfar, Meysam; Woelfer, Marie; Réus, Gislaine Z.; Quevedo, João; Walter, Martin; Kim, Yong Ku.

In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 94, 109668, 30.08.2019.

Research output: Contribution to journalReview article

@article{b915d91c648a4695898d0fe46ca13f18,
title = "The role of NMDA receptor in neurobiology and treatment of major depressive disorder: Evidence from translational research",
abstract = "There is accumulating evidence demonstrating that dysfunction of glutamatergic neurotransmission, particularly via N-methyl-d-aspartate (NMDA) receptors, is involved in the pathophysiology of major depressive disorder (MDD). Several studies have revealed an altered expression of NMDA receptor subtypes and impaired NMDA receptor-mediated intracellular signaling pathways in brain circuits of patients with MDD. Clinical studies have demonstrated that NMDA receptor antagonists, particularly ketamine, have rapid antidepressant effects in treatment-resistant depression, however, neurobiological mechanisms are not completely understood. Growing body of evidence suggest that signal transduction pathways involved in synaptic plasticity play critical role in molecular mechanisms underlying rapidly acting antidepressant properties of ketamine and other NMDAR antagonists in MDD. Discovering the molecular mechanisms underlying the unique antidepressant actions of ketamine will facilitate the development of novel fast acting antidepressants which lack undesirable effects of ketamine. This review provides a critical examination of the NMDA receptor involvement in the neurobiology of MDD including analyses of alterations in NMDA receptor subtypes and their interactive signaling cascades revealed by postmortem studies. Furthermore, to elucidate mechanisms underlying rapid-acting antidepressant properties of NMDA receptor antagonists we discussed their effects on the neuroplasticity, mostly based on signaling systems involved in synaptic plasticity of mood-related neurocircuitries.",
keywords = "Ketamine, Major depressive disorder, Memantine, NMDA receptor, Synaptic plasticity",
author = "Meysam Amidfar and Marie Woelfer and R{\'e}us, {Gislaine Z.} and Jo{\~a}o Quevedo and Martin Walter and Kim, {Yong Ku}",
year = "2019",
month = "8",
day = "30",
doi = "10.1016/j.pnpbp.2019.109668",
language = "English",
volume = "94",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - The role of NMDA receptor in neurobiology and treatment of major depressive disorder

T2 - Evidence from translational research

AU - Amidfar, Meysam

AU - Woelfer, Marie

AU - Réus, Gislaine Z.

AU - Quevedo, João

AU - Walter, Martin

AU - Kim, Yong Ku

PY - 2019/8/30

Y1 - 2019/8/30

N2 - There is accumulating evidence demonstrating that dysfunction of glutamatergic neurotransmission, particularly via N-methyl-d-aspartate (NMDA) receptors, is involved in the pathophysiology of major depressive disorder (MDD). Several studies have revealed an altered expression of NMDA receptor subtypes and impaired NMDA receptor-mediated intracellular signaling pathways in brain circuits of patients with MDD. Clinical studies have demonstrated that NMDA receptor antagonists, particularly ketamine, have rapid antidepressant effects in treatment-resistant depression, however, neurobiological mechanisms are not completely understood. Growing body of evidence suggest that signal transduction pathways involved in synaptic plasticity play critical role in molecular mechanisms underlying rapidly acting antidepressant properties of ketamine and other NMDAR antagonists in MDD. Discovering the molecular mechanisms underlying the unique antidepressant actions of ketamine will facilitate the development of novel fast acting antidepressants which lack undesirable effects of ketamine. This review provides a critical examination of the NMDA receptor involvement in the neurobiology of MDD including analyses of alterations in NMDA receptor subtypes and their interactive signaling cascades revealed by postmortem studies. Furthermore, to elucidate mechanisms underlying rapid-acting antidepressant properties of NMDA receptor antagonists we discussed their effects on the neuroplasticity, mostly based on signaling systems involved in synaptic plasticity of mood-related neurocircuitries.

AB - There is accumulating evidence demonstrating that dysfunction of glutamatergic neurotransmission, particularly via N-methyl-d-aspartate (NMDA) receptors, is involved in the pathophysiology of major depressive disorder (MDD). Several studies have revealed an altered expression of NMDA receptor subtypes and impaired NMDA receptor-mediated intracellular signaling pathways in brain circuits of patients with MDD. Clinical studies have demonstrated that NMDA receptor antagonists, particularly ketamine, have rapid antidepressant effects in treatment-resistant depression, however, neurobiological mechanisms are not completely understood. Growing body of evidence suggest that signal transduction pathways involved in synaptic plasticity play critical role in molecular mechanisms underlying rapidly acting antidepressant properties of ketamine and other NMDAR antagonists in MDD. Discovering the molecular mechanisms underlying the unique antidepressant actions of ketamine will facilitate the development of novel fast acting antidepressants which lack undesirable effects of ketamine. This review provides a critical examination of the NMDA receptor involvement in the neurobiology of MDD including analyses of alterations in NMDA receptor subtypes and their interactive signaling cascades revealed by postmortem studies. Furthermore, to elucidate mechanisms underlying rapid-acting antidepressant properties of NMDA receptor antagonists we discussed their effects on the neuroplasticity, mostly based on signaling systems involved in synaptic plasticity of mood-related neurocircuitries.

KW - Ketamine

KW - Major depressive disorder

KW - Memantine

KW - NMDA receptor

KW - Synaptic plasticity

UR - http://www.scopus.com/inward/record.url?scp=85067500241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067500241&partnerID=8YFLogxK

U2 - 10.1016/j.pnpbp.2019.109668

DO - 10.1016/j.pnpbp.2019.109668

M3 - Review article

VL - 94

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

M1 - 109668

ER -